WallStreetZenWallStreetZen

NASDAQ: ERAS
Erasca Inc Stock

Overview
ForecastEarningsDividendOwnership
$2.86-0.13 (-4.35%)
Updated Sep 6, 2024
ERAS Price
$2.86
Fair Value Price
$0.25
Market Cap
$807.96M
52 Week Low
$1.51
52 Week High
$3.45
P/E
-3.14x
P/B
1.79x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$158.28M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$111M
Beta
1.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ERAS Overview

Erasca, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca's therapeutic strategies are (1) target key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) target RAS directly; and (3) target escape routes that emerge in response to treatment. The company's lead candidates include ERAS-007, ERAS-601, and ERAS-801. Erasca was incorporated in 2018 and is headquartered in San Diego, CA.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ERAS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ERAS ($2.86) is overvalued by 1,054.15% relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ERAS ($2.86) is not significantly undervalued (1,054.15%) relative to our estimate of its Fair Value price of $0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ERAS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ERAS due diligence checks available for Premium users.

Be the first to know about important ERAS news, forecast changes, insider trades & much more!

ERAS News

Valuation

ERAS fair value

Fair Value of ERAS stock based on Discounted Cash Flow (DCF)
Price
$2.86
Fair Value
$0.25
Overvalued by
1,054.15%
ERAS ($2.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ERAS ($2.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ERAS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ERAS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.14x
Industry
-46.85x
Market
24.57x

ERAS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.79x
Industry
6.22x
ERAS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ERAS's financial health

Profit margin

Revenue
$0.0
Net Income
-$63.2M
Profit Margin
0%
ERAS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$525.7M
Liabilities
$74.7M
Debt to equity
0.17
ERAS's short-term assets ($418.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ERAS's short-term assets ($418.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ERAS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$29.2M
Investing
-$86.6M
Financing
$211.9M
ERAS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ERAS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ERAS$807.96M-4.35%-3.14x1.79x
IMNM$813.14M-4.78%-1.76x3.20x
ZYME$821.31M-1.70%-7.66x2.02x
FDMT$783.18M-2.84%-6.55x1.33x
PLRX$782.51M-3.60%-4.17x1.99x
View Top Biotech Stocks

Erasca Stock FAQ

What is Erasca's quote symbol?

(NASDAQ: ERAS) Erasca trades on the NASDAQ under the ticker symbol ERAS. Erasca stock quotes can also be displayed as NASDAQ: ERAS.

If you're new to stock investing, here's how to buy Erasca stock.

What is the 52 week high and low for Erasca (NASDAQ: ERAS)?

(NASDAQ: ERAS) Erasca's 52-week high was $3.45, and its 52-week low was $1.51. It is currently -17.1% from its 52-week high and 89.4% from its 52-week low.

How much is Erasca stock worth today?

(NASDAQ: ERAS) Erasca currently has 282,504,318 outstanding shares. With Erasca stock trading at $2.86 per share, the total value of Erasca stock (market capitalization) is $807.96M.

Erasca stock was originally listed at a price of $17.93 in Jul 19, 2021. If you had invested in Erasca stock at $17.93, your return over the last 3 years would have been -84.05%, for an annualized return of -45.77% (not including any dividends or dividend reinvestments).

How much is Erasca's stock price per share?

(NASDAQ: ERAS) Erasca stock price per share is $2.86 today (as of Sep 6, 2024).

What is Erasca's Market Cap?

(NASDAQ: ERAS) Erasca's market cap is $807.96M, as of Sep 7, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Erasca's market cap is calculated by multiplying ERAS's current stock price of $2.86 by ERAS's total outstanding shares of 282,504,318.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.